Makindo Medical Notes"One small step for man, one large step for Makindo" |
![]() |
---|---|
Download all this content in the Apps now Android App and Apple iPhone/Pad App | |
MEDICAL DISCLAIMER: The contents are under continuing development and improvements and despite all efforts may contain errors of omission or fact. This is not to be used for the assessment, diagnosis, or management of patients. It should not be regarded as medical advice by healthcare workers or laypeople. It is for educational purposes only. Please adhere to your local protocols. Use the BNF for drug information. If you are unwell please seek urgent healthcare advice. If you do not accept this then please do not use the website. Makindo Ltd. |
β οΈ Early diagnosis of Anthrax and the prompt initiation of combination antimicrobial therapy are critical for survival. π¨ Inhalational anthrax, in particular, carries a high mortality if untreated and requires immediate critical care involvement.
Scenario | Drug & Dose |
---|---|
ποΈ Cutaneous Anthrax (mild, non-systemic) |
Ciprofloxacin 500 mg PO BD (7β10 days)
OR
Doxycycline 100 mg PO BD (7β10 days)
π‘ If systemic features β use IV + combination therapy. |
π¨ Inhalational Anthrax / Systemic infection |
Ciprofloxacin 400 mg IV every 12h
OR
Doxycycline 100 mg IV every 12h
β Add 1β2 additional agents (rifampicin, clindamycin, or aminoglycoside) for synergy. Duration: β₯60 days (due to persistent spores). |
π§ Anthrax meningitis (suspected/confirmed) | Ciprofloxacin IV (as above) β Rifampicin IV β Clindamycin IV (Triple therapy recommended). |
π§΄ Post-exposure prophylaxis (PEP) |
Ciprofloxacin 500 mg PO BD for 60 days
OR
Doxycycline 100 mg PO BD for 60 days.
β Anthrax vaccine where available. |